PFIZER INC Contract Liability (Deferred Revenue)
PFIZER INC (PFE) had Contract Liability (Deferred Revenue) of $784.00 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-02-26
- 2025-12-31: Contract with Customer, Liability, Current $784.00M.
- 2025-09-28: Contract with Customer, Liability, Current $924.00M.
- 2025-06-29: Contract with Customer, Liability, Current $1.12B.
- 2025-03-30: Contract with Customer, Liability, Current $1.01B.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2025-12-31 | $784.00M 10-K · filed 2026-02-26 |
| 2025-09-28 | $924.00M 10-Q · filed 2025-11-04 |
| 2025-06-29 | $1.12B 10-Q · filed 2025-08-05 |
| 2025-03-30 | $1.01B 10-Q · filed 2025-05-05 |
| 2024-12-31 | $1.51B 10-K · filed 2026-02-26 |
| 2024-09-29 | $2.02B 10-Q · filed 2024-11-04 |
| 2024-06-30 | $2.53B 10-Q · filed 2024-08-05 |
| 2024-03-31 | $2.50B 10-Q · filed 2024-05-08 |
| 2023-12-31 | $2.70B 10-K · filed 2025-02-27 |
| 2023-10-01 | $2.20B 10-Q · filed 2023-11-08 |
| 2023-07-02 | $1.29B 10-Q · filed 2023-08-09 |
| 2023-04-02 | $1.75B 10-Q · filed 2023-05-10 |
| 2022-12-31 | $2.52B 10-K · filed 2024-02-22 |
| 2022-10-02 | $6.19B 10-Q · filed 2022-11-09 |
| 2022-07-03 | $3.80B 10-Q · filed 2022-08-10 |
| 2022-04-03 | $3.11B 10-Q · filed 2022-05-11 |
| 2021-12-31 | $3.07B 10-K · filed 2023-02-23 |
| 2021-10-03 | $3.53B 10-Q · filed 2021-11-12 |
| 2021-07-04 | $4.29B 10-Q · filed 2021-08-12 |
| 2021-04-04 | $2.05B 10-Q · filed 2021-05-13 |
| 2020-12-31 | $1.11B 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |